Immortal Time Bias or Sorafenib Effect in Elderly Patients With HCC?

被引：0
|
作者：
Sanoff, Hanna K. [1 ,2 ]
Chang, YunKyung [1 ,3 ]
Lund, Jennifer L. [1 ,4 ]
O'Neil, Bert H. [5 ]
Dusetzina, Stacie B. [1 ,6 ]
机构：
[1] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA
[2] Univ N Carolina, Dept Med, Div Hematol Oncol, Chapel Hill, NC 27599 USA
[3] QuintilesIMS, Res Triangle Pk, NC USA
[4] Univ N Carolina, Ctr Pharmacoepidemiol, Dept Epidemiol, Chapel Hill, NC USA
[5] Indiana Univ Sch Med, Div Hematol Oncol, Dept Med, Indianapolis, IN 46202 USA
[6] Univ N Carolina, Div Pharmaceut Outcomes & Policy, Eshelman Sch Pharm, Chapel Hill, NC USA
来源：
HEPATOLOGY | 2017年 / 66卷 / 02期
关键词：
D O I：
10.1002/hep.29250
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：678 / 679
页数：2
相关论文
共 50 条
  • [1] Immortal Time Bias or Sorafenib Effect in Elderly Patients With HCC? REPLY
    Parikh, Neehar D.
    Singal, Amit G.
    Lok, Anna S.
    Balkrishnan, Rajesh
    Shahinian, Vahakn
    Marshall, Vincent D.
    HEPATOLOGY, 2017, 66 (02) : 679 - 680
  • [2] | Immortal time bias
    Ranstam, Jonas
    Cook, Jonathan A.
    BRITISH JOURNAL OF SURGERY, 2022, 109 (07) : 642 - 642
  • [3] Immortal time bias
    Obel, Niels
    AIDS, 2015, 29 (07) : 859 - 860
  • [4] Immortal time bias affects effect size estimates
    Zheng, Q.
    Otahal, P.
    Cox, I
    De Graaff, B.
    Campbell, J.
    Ahmad, H.
    Walters, E.
    Palmer, A.
    RESPIROLOGY, 2023, 28 : 170 - 171
  • [5] Immortal time bias in pharmacoepidemiology
    Suissa, Samy
    AMERICAN JOURNAL OF EPIDEMIOLOGY, 2008, 167 (04) : 492 - 499
  • [6] Outcomes and safety of sorafenib in elderly patients with advanced hepatocellular carcinoma (HCC)
    Ziogas, Dimitrios
    Thillai, Kiruthikah
    Korantzis, Ippokratis
    Chowdhury, M. H. Ruhe
    Papadatos-Pastos, Dionysios
    Suddle, Abid
    O'Grady, John
    Heaton, Nigel
    Ross, Paul J.
    Sarker, Debashis
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [7] Efficacy and safety of sorafenib (SFN) in elderly patients with hepatocellular carcinoma (HCC)
    Gomes Da Fonseca, L.
    Nader Marta, G.
    Braghiroli, M. I.
    Hoff, P. M.
    Sabbaga, J.
    ANNALS OF ONCOLOGY, 2018, 29
  • [8] Outcomes and safety of sorafenib in elderly patients with advanced hepatocellular carcinoma (HCC)
    Ziogas, Dimitris
    Thillai, Kiruthikah
    Papadatos-Pastos, Dionysios
    Chowdhury, Mahfuja Hussain Ruhe
    Korantzis, Ippokratis
    Manickavasagar, Thubeena
    Suddle, Abid
    O'Grady, John
    Heaton, Nigel
    Ross, Paul J.
    Sarker, Debashis
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [9] Immortal Time Bias in Epidemiology
    Platt, R. W.
    Hutcheon, J. A.
    Suissa, S.
    CURRENT EPIDEMIOLOGY REPORTS, 2019, 6 (01) : 23 - 27
  • [10] Immortal Time Bias in Epidemiology
    R. W. Platt
    J. A. Hutcheon
    S. Suissa
    Current Epidemiology Reports, 2019, 6 : 23 - 27
12345